Unlocking the full potential of cell therapies for patients around the world

The Future of Cell Therapies

Through the complementary application of biological insights and technological advancements, we aim to unlock the transformative potential of cell therapies. Our proprietary Cell Squeeze ® technology effectively delivers a variety of therapeutic cargo to cells at scale while preserving cell function, thus opening opportunities to generate new classes of cell therapies across oncology, autoimmune and infectious diseases.
Discover our Technology

Enrolling Oncology Clinical Trials

Our cell therapies in development seek to put patients’ immune systems to work against disease. Learn more about our three clinical trials targeting HPV16+ solid tumors.

Antigen Presenting Cells

SQZ® APC Platform

Our SQZ® Antigen Presenting Cell (APC) Phase 1/2 trial for HPV16+ solid tumors is enrolling patients in its combination phase with checkpoint inhibitors. Learn more about how this therapeutic candidate uses a patient’s own white blood cells and peptide antigens to activate CD8 T cells against disease.

Visit our Patient Page

Visit our Patient Page

Enhanced Antigen Presenting Cells

SQZ® eAPC Platform

Our SQZ® enhanced APC (eAPC) Phase 1/2 trial (COMMANDER-001) for HPV16+ solid tumors is enrolling in its dose escalation monotherapy phase. Learn more about how this therapeutic candidate uses a patient’s own white blood cells and multiple mRNAs to activate CD8 T cells against disease.

Visit our Patient Page

Visit our Patient Page

Activating Antigen Carriers

SQZ® AAC Platform

Our SQZ® Activating Antigen Carrier (AAC) Phase 1/2 trial (ENVOY-001) for HPV16+ solid tumor is enrolling in its dose escalation phase. Learn more about how this therapeutic candidate uses a patient’s own red blood cells, antigens, and adjuvant to activate CD8 T cells against disease.

Visit our Patient Page

Visit our Patient Page
APC
eAPC
AAC

#HOWCELLSWORK Series

We developed the #HowCellsWork education series to support patients, families, and caregivers who want to further understand the therapeutic potential of cell therapies. Explore and enjoy our illustrated series.

Oncology

See how our cells interact with tumors and can ultimately help destroy them

Autoimmune Diseases

Our immune cells can drive autoimmune disease but can also be the solution

Regenerative Medicine

Cells can transform into other cell types, enabling the potential for regenerative medicine

See More

Latest News

December 06, 2022

Business Wire

POSTER: COMMANDER-001: Initial safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors

December 06, 2022

Business Wire

SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress

December 06, 2022

Business Wire

POSTER: Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors

See More